PDCD1 and cancer: Immune checkpoint inhibitors (ICIs), which inhibit programmed cell death 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), have shown success in treating many cancers.